Wanbury Limited — Updates, 18-02-2025: Press Release

Wanbury Ltd. reported notable financial results for Q3 and the nine months of FY25, revealing a revenue decline to ₹133.5 Cr, down 8.3% YoY, largely due to a 30-day shutdown of its Tanuku manufacturing facility for major upgrades. EBITDA dropped to ₹14.8 Cr, with a margin contraction to 11.1%. Net profit was significantly impacted, falling to ₹1.2 Cr compared to ₹10.3 Cr in the same quarter last year.

Key developments include the successful completion of the Brazilian Health Authority audit for the Tanuku plant, enhancing market credibility. The company appointed industry veterans, including Rashesh Patel as Corporate Director for India Formulation, expected to leverage his prior successes to drive growth. Recently, Wanbury entered a refinancing agreement with Emerging India Credit Opportunities Fund II, planning to raise ₹200 Cr through non-convertible debentures to support capital expenditure and working capital needs.

Investors should monitor the potential for recovery as operational disruptions are resolved, alongside strategic hires that may enhance competitiveness and growth prospects in the pharmaceutical sector.